Skip to content

Beverage for Immune Support

Amunizer for Immune Support: A Randomized, Placebo Controlled, Double Blind Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05566314
Enrollment
160
Registered
2022-10-04
Start date
2022-09-22
Completion date
2023-03-31
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune

Brief summary

Evaluate the effects of a beverage supplement on immune health over an 8 week intervention using either a placebo or active supplement.

Interventions

DIETARY_SUPPLEMENTAmunizer

12 oz. herbal, probiotic and antioxidant herbal beverage

OTHERPlacebo

12 oz. flavored beverage

Sponsors

Nutraceuticals Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

\-

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Number of days with symptoms documented by the Franklin Health Immune Inventory (FHII)from baseline to the end of the study, 8 weeksThe FHII measures incidence and severity of over 50 signs of immune health. Days with symptoms will range from 0 to 56 days, indicating no sickness to sick every day.
Severity of symptoms documented by the FHIIfrom baseline to the end of the study, 8 weeksThe FHII measures incidence and severity of over 50 signs of immune health. Symptom severity is measured on a likert scale with higher scores indicating greater symptom severity.

Secondary

MeasureTime frameDescription
Incidence and severity on the dermal symptom subscale of the FHIIfrom baseline to the end of the study, 8 weeksThe FHII subscale measures 9 dermal symptoms on a likert scale with higher scores indicating greater severity.
Change from baseline scores on the Franklin Energy Level Inventory8 weekThe Franklin Energy Level Inventory measures signs of energy across 6 subdomains, with higher scores indicating greater levels of energy.
Incidence and severity on the upper respiratory symptom subscale of the FHIIfrom baseline to the end of the study, 8 weeksThe FHII subscale measures 16 respiratory symptoms on a likert scale with higher scores indicating greater severity.
Change from baseline scores on the Franklin Mood Scale8 weekThe Franklin Mood Scale measures mood stats across 4 subdomains, with higher scores indicating improvements to mood.
Change from baseline scores on the Franklin Sleep Quality Inventory8 weekThe Franklin Sleep Quality Inventory measures sleep quality across 7 subdomains, with higher scores indicating higher quality sleep.
Incidence and severity on the gastrointestinal symptom subscale of the FHIIfrom baseline to the end of the study, 8 weeksThe FHII subscale measures 11 gastrointestinal symptoms on a likert scale with higher scores indicating greater severity.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026